Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP. Trottier B, et al. Among authors: bertasso a. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21. doi: 10.1097/01.qai.0000185313.48933.2c. J Acquir Immune Defic Syndr. 2005. PMID: 16280695 Clinical Trial.
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.
Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O'Hearn M, Reynes J, Arastéh K, Chung J, Rowell L, Guimaraes D, Bertasso A; TORO 1 and TORO 2 Study Groups. Cooper DA, et al. Among authors: bertasso a. HIV Med. 2011 Jan;12(1):31-9. doi: 10.1111/j.1468-1293.2010.00845.x. HIV Med. 2011. PMID: 20497250 Free article. Clinical Trial.
Adherence to enfuvirtide and its impact on treatment efficacy.
Rockstroh J, Dejesus E, Donatacci L, Wat C, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Guimaraes D, Wilkinson M, Thommes J, Rowell L, Demasi R, Salgo M. Rockstroh J, et al. Among authors: bertasso a. AIDS Res Hum Retroviruses. 2008 Feb;24(2):141-8. doi: 10.1089/aid.2006.0231. AIDS Res Hum Retroviruses. 2008. PMID: 18240965 Clinical Trial.
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Gane EJ, Pockros PJ, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, Zhou J, Yetzer ES, Ballester R, Dwyer C, Tong X, Nájera I, Bertasso A, Hammond J, Kindrick A, Morcos PN, Smith P, Stancic S, Shulman NS. Gane EJ, et al. Among authors: bertasso a. Liver Int. 2015 Jan;35(1):79-89. doi: 10.1111/liv.12588. Epub 2014 Jun 19. Liver Int. 2015. PMID: 24814388 Clinical Trial.
Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device.
Varunok P, Lawitz E, Beavers KL, Matusow G, Leong R, Lambert N, Bernaards C, Solsky J, Brennan BJ, Wat C, Bertasso A. Varunok P, et al. Among authors: bertasso a. Patient Prefer Adherence. 2011;5:587-99. doi: 10.2147/PPA.S26566. Epub 2011 Nov 24. Patient Prefer Adherence. 2011. PMID: 22163158 Free PMC article.
29 results